Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$8.21 +0.01 (+0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$8.20 -0.02 (-0.18%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$8.20
$8.38
50-Day Range
$7.20
$8.67
52-Week Range
$4.99
$10.67
Volume
751,098 shs
Average Volume
1.33 million shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 498th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is -54.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is -54.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.00% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.00% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 19 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,753,094.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH stock has decreased by 8.6% and is now trading at $8.21.
View the best growth stocks for 2025 here
.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.01. Aurinia Pharmaceuticals's revenue was up 37.6% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Aurinia Pharmaceuticals include Segall Bryant & Hamill LLC (0.27%), Bank of New York Mellon Corp (0.26%), Rice Hall James & Associates LLC (0.17%) and Sunbelt Securities Inc. (0.09%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, George M Milne Jr, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
8/01/2024
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+40.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
74.64
P/E Growth
N/A
Net Income
$-78,020,000.00
Pretax Margin
-9.14%

Debt

Sales & Book Value

Annual Sales
$235.13 million
Price / Cash Flow
N/A
Book Value
$2.63 per share
Price / Book
3.12

Miscellaneous

Free Float
137,022,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.16

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners